These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 20884063)

  • 1. A pooled analysis of two randomised, placebo-controlled studies of extended release quetiapine fumarate adjunctive to antidepressant therapy in patients with major depressive disorder.
    Bauer M; El-Khalili N; Datto C; Szamosi J; Eriksson H
    J Affect Disord; 2010 Dec; 127(1-3):19-30. PubMed ID: 20884063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of extended release quetiapine fumarate monotherapy in patients with major depressive disorder: a pooled analysis of two 6-week, double-blind, placebo-controlled studies.
    Weisler RH; Montgomery SA; Earley WR; Szamosi J; Lazarus A
    Int Clin Psychopharmacol; 2012 Jan; 27(1):27-39. PubMed ID: 22027845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in major depressive disorder: a placebo-controlled, randomized study.
    Bortnick B; El-Khalili N; Banov M; Adson D; Datto C; Raines S; Earley W; Eriksson H
    J Affect Disord; 2011 Jan; 128(1-2):83-94. PubMed ID: 20691481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study.
    El-Khalili N; Joyce M; Atkinson S; Buynak RJ; Datto C; Lindgren P; Eriksson H
    Int J Neuropsychopharmacol; 2010 Aug; 13(7):917-32. PubMed ID: 20175941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quetiapine XR efficacy and tolerability as monotherapy and as adjunctive treatment to conventional antidepressants in the acute and maintenance treatment of major depressive disorder: a review of registration trials.
    McIntyre RS; Muzina DJ; Adams A; Lourenco MT; Law CW; Soczynska JK; Woldeyohannes HO; Nathanson J; Kennedy SH
    Expert Opin Pharmacother; 2009 Dec; 10(18):3061-75. PubMed ID: 19954275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term functioning and sleep quality in patients with major depressive disorder treated with extended-release quetiapine fumarate.
    Sheehan DV; Locklear J; Svedsäter H; Datto C
    Int Clin Psychopharmacol; 2012 Sep; 27(5):239-48. PubMed ID: 22859063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: a randomized, placebo-controlled trial.
    Liebowitz M; Lam RW; Lepola U; Datto C; Sweitzer D; Eriksson H
    Depress Anxiety; 2010 Oct; 27(10):964-76. PubMed ID: 20734365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quetiapine XR: current status for the treatment of major depressive disorder.
    Pae CU; Sohi MS; Seo HJ; Serretti A; Patkar AA; Steffens DC; Masand PS
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Oct; 34(7):1165-73. PubMed ID: 20307622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: pooled data from randomised, double-blind, placebo-controlled studies.
    Meulien D; Huizar K; Brecher M
    Hum Psychopharmacol; 2010 Mar; 25(2):103-15. PubMed ID: 20196185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The extended-release formulation of quetiapine fumarate (quetiapine XR) adjunctive treatment in partially responsive generalized anxiety disorder (GAD): An open label naturalistic study.
    Gabriel A
    Clin Ter; 2011; 162(2):113-8. PubMed ID: 21533316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of potentially predictive factors of efficacy of adjunct extended-release quetiapine fumarate in patients with major depressive disorder.
    Bauer M; Thase ME; Liu S; Earley W; Eriksson H
    J Psychopharmacol; 2015 May; 29(5):565-74. PubMed ID: 25257148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pooled analysis of sustained response rates for extended release quetiapine fumarate as monotherapy or adjunct to antidepressant therapy in patients with major depressive disorder.
    Vieta E; Bauer M; Montgomery S; McIntyre RS; Szamosi J; Earley WR; Eriksson H
    J Affect Disord; 2013 Sep; 150(2):639-43. PubMed ID: 23497790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of extended release quetiapine fumarate monotherapy in elderly patients with major depressive disorder: secondary analyses in subgroups of patients according to baseline anxiety, sleep disturbance, and pain levels.
    Montgomery SA; Altamura AC; Katila H; Datto C; Szamosi J; Eriksson H
    Int Clin Psychopharmacol; 2014 Mar; 29(2):93-105. PubMed ID: 24162081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sexual functioning in patients with major depressive disorder in randomized placebo-controlled studies of extended release quetiapine fumarate.
    Clayton AH; Locklear JC; Svedsäter H; McIntyre RS
    CNS Spectr; 2014 Apr; 19(2):182-96. PubMed ID: 24067192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study.
    Bauer M; Pretorius HW; Constant EL; Earley WR; Szamosi J; Brecher M
    J Clin Psychiatry; 2009 Apr; 70(4):540-9. PubMed ID: 19358791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extended-release quetiapine fumarate in the treatment of patients with major depressive disorder: adjunct therapy.
    Weisler R; McIntyre RS; Bauer M
    Expert Rev Neurother; 2013 Nov; 13(11):1183-200. PubMed ID: 24175721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of adjunct extended-release quetiapine fumarate on sleep disturbance and quality in patients with major depressive disorder and an inadequate response to on-going antidepressant therapy.
    Bauer M; McIntyre RS; Szamosi J; Eriksson H
    Int J Neuropsychopharmacol; 2013 Sep; 16(8):1755-65. PubMed ID: 23672772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pooled analysis of adjunct extended-release quetiapine fumarate in patients with major depressive disorder according to ongoing SSRI or SNRI treatment.
    Bauer M; Demyttenaere K; El-Khalili N; Thase ME; Papakostas GI; Szamosi J; Earley WR; Eriksson H
    Int Clin Psychopharmacol; 2014 Jan; 29(1):16-25. PubMed ID: 24108148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extended release quetiapine fumarate as adjunct to antidepressant therapy in patients with major depressive disorder: pooled analyses of data in patients with anxious depression versus low levels of anxiety at baseline.
    Bandelow B; Bauer M; Vieta E; El-Khalili N; Gustafsson U; Earley WR; Eriksson H
    World J Biol Psychiatry; 2014 Feb; 15(2):155-66. PubMed ID: 24506289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of extended-release quetiapine fumarate monotherapy in the treatment of patients with major depressive disorder.
    Weisler R; McIntyre RS
    Expert Rev Neurother; 2013 Nov; 13(11):1161-82. PubMed ID: 24175720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.